Iovance Biotherapeutics's total assets for Q4 2025 were $913.17M, an increase of 0.91% from the previous quarter. DE:2LB total liabilities were $214.59M for the fiscal quarter, a 5.88% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.